Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 7/20 | 0.61 |
| ▸ | NTRK1 | P04629 | 6/20 | 0.57 |
| ▸ | MOGAT2 | Q3SYC2 | 1/20 | 0.56 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.54 |
| ▸ | AKT2 | P31751 | 1/20 | 0.53 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.53 |
| ▸ | JAK3 | P52333 | 1/20 | 0.53 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.53 |
| ▸ | MGAT2 | Q10469 | 2/20 | 0.52 |
| ▸ | RET | P07949 | 2/20 | 0.52 |
| ▸ | FLT3 | P36888 | 1/20 | 0.52 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.52 |
| ▸ | FLT1 | P17948 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5728621 | 0.88 | PDPK1 (0.69) | PDPK1NTRK1AURKBPDGFRBAKT2 | |
| SCHEMBL5728620 | 0.88 | PDPK1 (0.69) | PDPK1NTRK1AURKBPDGFRBAKT2 | |
| SCHEMBL5358368 | 0.86 | MOGAT2 (0.61) | MOGAT2TLK2MGAT2 | |
| SCHEMBL5357745 | 0.85 | MOGAT2 (0.58) | MOGAT2MGAT2 | |
| SCHEMBL7137726 | 0.84 | MOGAT2 (0.57) | PDPK1NTRK1MOGAT2TLK2MGAT2 | |
| SCHEMBL5361553 | 0.84 | MOGAT2 (0.57) | PDPK1NTRK1MOGAT2TLK2MGAT2 | |
| SCHEMBL5365019 | 0.83 | TLK2 (0.67) | NTRK1MOGAT2TLK2MGAT2 | |
| SCHEMBL5358489 | 0.83 | RPS6KA3 (0.56) | MOGAT2MGAT2 | |
| SCHEMBL5358922 | 0.83 | PDPK1 (0.63) | PDPK1NTRK1MOGAT2AURKBJAK3 | |
| SCHEMBL5357707 | 0.82 | MOGAT2 (0.57) | NTRK1MOGAT2TLK2MGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | FRK, PTK2, DSTYK | PDPK1 31/4885NTRK1 223/4885MOGAT2 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.